Cytosorbents (NASDAQ:CTSO) Receives Buy Rating from D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $10.00 price target on the medical research company’s stock.

Several other research analysts have also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research note on Tuesday, October 14th. HC Wainwright cut their target price on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Stock Down 0.8%

NASDAQ CTSO traded down $0.01 on Friday, reaching $0.66. The company had a trading volume of 135,463 shares, compared to its average volume of 164,530. The firm has a market capitalization of $41.42 million, a PE ratio of -3.88 and a beta of 1.28. The firm has a 50-day moving average of $0.88 and a 200-day moving average of $0.96. Cytosorbents has a 1 year low of $0.60 and a 1 year high of $1.61. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.34 and a quick ratio of 1.96.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Friday, January 3rd. The medical research company reported ($0.08) earnings per share for the quarter. The firm had revenue of $8.61 million for the quarter. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. On average, equities research analysts anticipate that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Trading of Cytosorbents

Several hedge funds have recently bought and sold shares of the company. Avenir Corp boosted its stake in Cytosorbents by 0.3% during the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after purchasing an additional 13,619 shares during the period. Vanguard Group Inc. grew its holdings in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after buying an additional 79,535 shares in the last quarter. CM Management LLC grew its holdings in Cytosorbents by 3.1% in the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after buying an additional 38,128 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Cytosorbents in the 3rd quarter valued at approximately $105,000. Finally, Goldman Sachs Group Inc. raised its stake in Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.